1402664-68-9Relevant academic research and scientific papers
2,3-DIHYDRO-1H-PYRROLO[3,4-C]PYRIDIN-1-ONE DERIVATIVES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER
-
Page/Page column 50, (2020/06/05)
This invention relates to 2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-1-one derivatives of general Formula (I) and pharmaceutically acceptable salts thereof, as hematopoietic progenitor kinase 1 (HPK1) inhibitors, in which R1, R1a, R2, R3, R4, and (R5)a are as defined herein, to pharmaceutical compositions comprising such compounds and and to compositions for the treatment of abnormal cell growth, including cancer. A specific exemplary compound is e.g. 4-[(methylamino)methyl]-6- [methyl(propan-2-yl)amino]-2-[6-(4-propyl-4H-l,2,4-triazol-3-yl) pyridin-2-yl]-2,3-dihydro-lH-pyrrolo[3,4-c]pyridin-l-one. The present description discloses the preparation of exemplary compounds as well as pharmacological data thereof (e.g. pages 82 to 211; examples 1 to 188; tables 1 to 5).
Tris(hetero)arylpyrazoles and use thereof
-
Page/Page column 36; 37, (2016/02/26)
The present invention relates to new tri(hetero)aryl pyrazoles, methods for their preparation, their use for treating and/or preventing diseases as well as their use in the preparation of drugs for treating and/or preventing diseases, in particular retrov
TRIS(HETERO)ARYLPYRAZOLES AND USE THEREOF
-
Paragraph 0502; 0504; 0505; 0506, (2015/07/27)
The present invention relates to new tri(hetero)aryl pyrazoles, methods for their preparation, their use for treating and/or preventing diseases as well as their use in the preparation of drugs for treating and/or preventing diseases, in particular retrov
